1. Home
  2. OCGN
  3. OCGN News

Latest Ocugen Inc. (OCGN) News on January 4, 2025

5 Biotech Breakthrough Stocks to Watch in 2025
OCGN

Zacks

12 days ago

5 Biotech Breakthrough Stocks to Watch in 2025

OCGN

MT Newswires

16 days ago

Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
OCGN

GlobeNewswire

17 days ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
OCGN

GlobeNewswire

24 days ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
OCGN

GlobeNewswire

a month ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

OCGN

MT Newswires

a month ago

Ocugen's Eye Disease Treatment Receives Orphan Drug Designation in Europe for Retinopathies

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
OCGN

GlobeNewswire

a month ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
OCGN

GlobeNewswire

2 months ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
OCGN

Zacks

2 months ago

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

OCGN

Associated Press Finance

2 months ago

Ocugen: Q3 Earnings Snapshot

OCGN

Thomson Reuters StreetEvents

2 months ago

Q3 2024 Ocugen Inc Earnings Call

Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
OCGN

GuruFocus.com

2 months ago

Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Ocugen (OCGN) Q3 2024 Earnings Call Transcript
OCGN

Motley Fool

2 months ago

Ocugen (OCGN) Q3 2024 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2024 Financial Results
OCGN

GlobeNewswire

2 months ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen Secures $30 Million in Debt Funding
OCGN

GlobeNewswire

2 months ago

Ocugen Secures $30 Million in Debt Funding

Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%
OCGN

Simply Wall St.

2 months ago

Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
OCGN

GlobeNewswire

2 months ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

OCGN

MT Newswires

2 months ago

Ocugen Receives Approval to Begin Dosing in Phase 2 Trial of CU410ST to Treat Genetic Eye Disease

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
OCGN

GlobeNewswire

2 months ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
OCGN

GlobeNewswire

3 months ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

State Street Corp's Strategic Acquisition of Shares in Ocugen Inc
OCGN

GuruFocus.com

3 months ago

State Street Corp's Strategic Acquisition of Shares in Ocugen Inc

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
OCGN

GlobeNewswire

3 months ago

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
OCGN

GuruFocus.com

3 months ago

Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

OCGN

MT Newswires

3 months ago

Ocugen Says FDA Lifts Clinical Hold for Diabetic Macular Edema Treatment Study

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
OCGN

GlobeNewswire

3 months ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
OCGN

GlobeNewswire

3 months ago

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
OCGN

GlobeNewswire

3 months ago

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
OCGN

GlobeNewswire

4 months ago

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
OCGN

GlobeNewswire

4 months ago

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
OCGN

GlobeNewswire

4 months ago

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

OCGN

MT Newswires

4 months ago

Sector Update: Health Care Stocks Steady Premarket Wednesday

OCGN

MT Newswires

4 months ago

Ocugen Completes Dosing in Third Cohort in Trial of Stargardt Disease Treatment

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
OCGN

GlobeNewswire

4 months ago

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
OCGN

Zacks

4 months ago

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up

OCGN

MT Newswires

4 months ago

Ocugen Says Health Canada Clears OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
OCGN

GlobeNewswire

4 months ago

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

OCGN

Thomson Reuters StreetEvents

5 months ago

Q2 2024 Ocugen Inc Earnings Call

Ocugen (OCGN) Q2 2024 Earnings Call Transcript
OCGN

Motley Fool

5 months ago

Ocugen (OCGN) Q2 2024 Earnings Call Transcript

Ocugen Provides Business Update with Second Quarter 2024 Financial Results
OCGN

GlobeNewswire

5 months ago

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

OCGN

Associated Press Finance

5 months ago

Ocugen: Q2 Earnings Snapshot

OCGN

MT Newswires

5 months ago

Ocugen Gets Expanded Access Program Approval for OCU400 From FDA

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
OCGN

GlobeNewswire

5 months ago

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

OCGN

MT Newswires

5 months ago

Ocugen Closes $35 Million Common Stock Offering

OCGN

MT Newswires

5 months ago

Ocugen Prices $35 Million Common Stock Offering

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
OCGN

GlobeNewswire

5 months ago

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

Ocugen, Inc. Announces Proposed Public Offering of Common Stock
OCGN

GlobeNewswire

5 months ago

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
OCGN

GlobeNewswire

5 months ago

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
OCGN

GlobeNewswire

5 months ago

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
OCGN

Motley Fool

6 months ago

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
OCGN

Zacks

6 months ago

Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?

OCGN

MT Newswires

6 months ago

Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
OCGN

GlobeNewswire

6 months ago

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
OCGN

GlobeNewswire

7 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
OCGN

Business Wire

7 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
OCGN

GlobeNewswire

7 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
OCGN

GlobeNewswire

7 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
OCGN

Simply Wall St.

7 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
OCGN

Reuters

7 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
OCGN

AFP

7 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed
OCGN

PR Newswire

7 months ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
OCGN

GlobeNewswire

7 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
OCGN

Zacks

7 months ago

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
OCGN

Zacks

7 months ago

Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why

OCGN

MT Newswires

7 months ago

Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
OCGN

GlobeNewswire

7 months ago

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

Ocugen to Present at BIO International Convention 2024
OCGN

GlobeNewswire

7 months ago

Ocugen to Present at BIO International Convention 2024

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
OCGN

GlobeNewswire

7 months ago

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole
OCGN

Motley Fool

7 months ago

1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole

Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
OCGN

Zacks

7 months ago

Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
OCGN

GlobeNewswire

8 months ago

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

OCGN

MT Newswires

8 months ago

Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
OCGN

GlobeNewswire

8 months ago

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

OCGN

GuruFocus.com

8 months ago

Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...

OCGN

Thomson Reuters StreetEvents

8 months ago

Q1 2024 Ocugen Inc Earnings Call

Ocugen Provides Business Update with First Quarter 2024 Financial Results
OCGN

GlobeNewswire

8 months ago

Ocugen Provides Business Update with First Quarter 2024 Financial Results

OCGN

Associated Press Finance

8 months ago

Ocugen: Q1 Earnings Snapshot

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
OCGN

GlobeNewswire

8 months ago

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

Ocugen to Present at May 2024 Investor Conferences
OCGN

GlobeNewswire

8 months ago

Ocugen to Present at May 2024 Investor Conferences

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
OCGN

GlobeNewswire

8 months ago

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
OCGN

GlobeNewswire

8 months ago

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

Can Ocugen Stock Keep Churning Higher?
OCGN

Motley Fool

8 months ago

Can Ocugen Stock Keep Churning Higher?

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
OCGN

GlobeNewswire

8 months ago

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
OCGN

Zacks

8 months ago

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
OCGN

GlobeNewswire

8 months ago

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
OCGN

GlobeNewswire

8 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
OCGN

GlobeNewswire

9 months ago

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
OCGN

GlobeNewswire

9 months ago

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
OCGN

GlobeNewswire

9 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
OCGN

Zacks

9 months ago

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
OCGN

GlobeNewswire

9 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
OCGN

GlobeNewswire

9 months ago

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

OCGN

Thomson Reuters StreetEvents

9 months ago

Q4 2023 Ocugen Inc Earnings Call

Ocugen (OCGN) Q4 2023 Earnings Call Transcript
OCGN

Motley Fool

9 months ago

Ocugen (OCGN) Q4 2023 Earnings Call Transcript

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
OCGN

GlobeNewswire

9 months ago

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
OCGN

GlobeNewswire

9 months ago

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
OCGN

GlobeNewswire

9 months ago

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
OCGN

GlobeNewswire

10 months ago

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
OCGN

GlobeNewswire

10 months ago

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
OCGN

Motley Fool

10 months ago

Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street

Ocugen to Present at Investing in Cures Summit
OCGN

GlobeNewswire

10 months ago

Ocugen to Present at Investing in Cures Summit

Share on Social Networks: